

---

**Neuland Laboratories Limited**  
Sanali Info Park, 'A' Block,  
Ground Floor, 8-2-120/113  
Road No. 2, Banjara Hills  
Hyderabad - 500 034,  
Telangana, India.

Tel: 040 30211600 / 23551081  
Fax: 040 30211602  
Email: [neuland@neulandlabs.com](mailto:neuland@neulandlabs.com)  
[www.neulandlabs.com](http://www.neulandlabs.com)

---

August 30, 2019

To  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai - 400 001

To  
The National Stock Exchange of India Ltd.  
Exchange Plaza,  
Bandra Kurla Complex, Bandra (E)  
Mumbai - 400 001

**Scrip Code: 524558**

**Scrip Code: NEULANLAB**

Dear Sirs,

Ref: Our letter dated June 21, 2019 on United States Food and Drug Administration (U.S.FDA) inspection at our Unit 1 manufacturing facility at Bonthapally, Hyderabad.

We refer to our letter dated June 21, 2019 and would like to inform you that the Company has received an Establishment Inspection Report (EIR) from the U.S.FDA for its manufacturing facility located at Bonthapally, Hyderabad. The facility was inspected from 17<sup>th</sup> to 21<sup>st</sup> June 2019. The inspection has now been closed by the U.S. FDA.

This is for your information and records.

Yours faithfully,  
For Neuland Laboratories Limited



**Sarada Bhamidipati**  
Company Secretary